- In May 2026, Biogen’s partner UCB reported positive Phase 3 PHOENYCS GO results for dapirolizumab pegol in moderate-to-severe active systemic lupus erythematosus, while Biogen and Denali ended development of BIIB122 for idiopathic Parkinson’s disease after the Phase 2b LUMA trial failed to show clinical benefit versus placebo.
- Together, these updates highlight how Biogen’s pipeline remains a mix of setbacks in broader neurodegeneration and promise in high-need autoimmune indications such as lupus.
- We’ll now examine how the encouraging lupus data, despite the Parkinson’s setback, may influence Biogen’s investment narrative and risk balance.
AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Biogen Investment Narrative Recap
To own Biogen today, you need to believe that its newer neurology and immunology launches can offset pressure in multiple sclerosis while the pipeline produces a few meaningful winners. The Parkinson’s setback with BIIB122 removes one potential neurology option, but the positive Phase 3 lupus data with dapirolizumab pegol helps rebalance the story toward high-need autoimmune disease. Overall, the impact on the near term narrative and main risk of overreliance on a handful of launches looks meaningful but not thesis breaking.
The lupus readout is especially relevant alongside Biogen’s broader immunology efforts, including nephrology data around EMPAVELI and felzartamab. Together, these programs point to a clearer second leg of value creation outside MS and Alzheimer’s, which could matter if competition and pricing pressure build in those markets. For shareholders, the key question is whether these newer autoimmune and renal assets can mature fast enough to support earnings while Biogen absorbs pipeline volatility elsewhere.
Yet, beneath the promising lupus headlines, there is a concentration risk in a small group of high-profile launches that investors should be aware of...
Read the full narrative on Biogen (it's free!)
Biogen's narrative projects $10.7 billion revenue and $2.2 billion earnings by 2029.
Uncover how Biogen's forecasts yield a $219.27 fair value, a 12% upside to its current price.
Exploring Other Perspectives
While consensus focuses on pipeline ups and downs, the most optimistic analysts were assuming roughly US$11.8 billion of revenue and US$2.5 billion of earnings by 2029, so BIIB122’s failure and lupus progress may push those expectations and the underlying risk of heavier R&D spending in very different directions depending on how you see Biogen’s next wave of drugs.
Explore 6 other fair value estimates on Biogen - why the stock might be worth 23% less than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.
Interested In Other Possibilities?
Our top stock finds are flying under the radar-for now. Get in early:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.
- Find 47 companies with promising cash flow potential yet trading below their fair value.
- Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com